Nialamide

Summary

Nialamide (CHEMBL1256841) is an approved small molecule (ATC N06AF02); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AF02
• Indications: 1 condition
• Chemistry: 298.34 Da · C16H18N4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1256841
Name	Nialamide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4472
ATC	N06AF02
Molecular formula	C16H18N4O2
Molecular weight	298.34
InChIKey	NOIIUHRQUVNIDD-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)CNC(=O)CCNNC(=O)C2=CC=NC=C2

IUPAC name: N-benzyl-3-[2-(pyridine-4-carbonyl)hydrazinyl]propanamide

Also known as: Nialamida, Nialamide, Niamid, NSC-124514, SID11111522, SID11111523, SID50104074, SID855800, SID90341025, SID85231151, SID56422110, nialamide

Patent coverage: 1,465 distinct patent families (5,414 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lysine-specific demethylase 4E, Survival motor neuron protein, Prelamin-A/C, Endonuclease 4, Thyrotropin receptor, Prostaglandin G/H synthase 1, Cytochrome P450 2D6, Nuclear factor NF-kappa-B p105 subunit, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 3A4, Cruzipain, Aldehyde dehydrogenase 1A1, Cytochrome P450 2C19, Cellular tumor antigen p53.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 25 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P25779	6.7	Potency	199.5	nM	CHEMBL_ACT_3974595
PTGS1	5.78	AC50	1655	nM	CHEMBL_ACT_25206112
SMN1	5.45	Potency	3548	nM	CHEMBL_ACT_3874636
P0A6C1	5.25	Potency	5623	nM	CHEMBL_ACT_4084671
TSHR	5.2	Potency	6310	nM	CHEMBL_ACT_3920041
TSHR	5.2	Potency	6310	nM	CHEMBL_ACT_4618365
LMNA	5.15	Potency	7080	nM	CHEMBL_ACT_3622103
CYP2D6	5.1	Potency	7943	nM	CHEMBL_ACT_4961709
CYP2D6	5.1	AC50	7943	nM	CHEMBL_ACT_6067327
PTGS1	5.08	AC50	8284	nM	CHEMBL_ACT_25205179
KDM4E	5.05	Potency	8912	nM	CHEMBL_ACT_3703233
CYP2C19	5	Potency	10000	nM	CHEMBL_ACT_4021084
CYP2C9	5	Potency	10000	nM	CHEMBL_ACT_5057422
CYP2C9	5	AC50	10000	nM	CHEMBL_ACT_6002558
CYP2C19	5	AC50	10000	nM	CHEMBL_ACT_6048328

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).